EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real‐world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR)

Martin Špaček iD, Lukáš Smolej, Martin Šimkovič, Lucie Nekvindová, Zlatuše Křístková, Yvona Brychtová, Anna Panovská, Stanislava Mašlejová, Lucie Bezděková, Dominika Écsiová, Pavel Vodárek, Jana Zuchnická und 12 weitere

British Journal of Haematology · 2023-07 · 202 (1) · 40-47

DOI: 10.1111/bjh.18736 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 27.03.2023. Verfasst von Martin Špaček und 23 weiteren Autor:innen. Beteiligte Einrichtung: 1st Department of Medicine - Haematology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Nové Město, Czech …. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministerstvo Zdravotnictví Ceské Republiky, Univerzita Karlova v Praze.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Idelalisib (idela), a phosphatidylinositol 3‐kinase inhibitor, and ibrutinib, a Bruton tyrosine kinase inhibitor, were the first oral targeted agents approved for relapsed/refractory (R/R) chronic lymphocytic leukaemia (CLL). However, no randomised trials of idelalisib plus rituximab (R‐idela) versus ibrutinib have been conducted. Therefore, we performed a real‐world retrospective analysis of patients with R/R CLL treated with R‐idela ( n = 171) or ibrutinib ( n = 244). The median age was 70 versus 69 years, with a median of two previous lines. There was a trend towards higher tumour protein p53 ( TP53 ) aberrations and complex karyotype in the R‐idela group (53% vs. 44%, p = 0.093; 57% vs. 46%, p = 0.083). The median progression‐free survival (PFS) was significantly longer with ibrutinib (40.5 vs. 22.0 months; p < 0.001); similarly to overall survival (OS; median 54.4 vs. 37.7 months, p = 0.04). In multivariate analysis, only PFS but not OS remained significantly different between the two agents. The most common reasons for treatment discontinuation included toxicity (R‐idela, 39.8%; ibrutinib, 22.5%) and CLL progression (27.5% vs. 11.1%). In conclusion, our data show significantly better efficacy and tolerability of ibrutinib over R‐idela in patients with R/R CLL treated in routine practice. The R‐idela regimen may still be considered a reasonable option in highly selected patients without a suitable treatment alternative.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellHumansAgedRituximabRetrospective StudiesRecurrenceRegistriesPurinesQuinazolinonesAdeninePiperidines

Stichwörter der Autor:innen

chronic lymphocytic leukaemiaibrutinibidelalisibreal-world evidencerituximab

Substanzen

RituximabidelalisibPurinesQuinazolinonesibrutinibAdeninePiperidines

Autor:innen und Institutionen

  • 1st Department of Medicine - Haematology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Nové Město, Czech Republic.
  • 4th Department of Internal Medicine - Haematology, University Hospital and Charles University Faculty of Medicine, Hradec Králové, Czech Republic.
  • Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic.
  • Department of Internal Medicine - Haematology and Oncology, University Hospital, Brno, Czech Republic.
  • Department of Haematooncology, University Hospital Ostrava, Ostrava, Czech Republic.
  • Department of Haematooncology, University Hospital Olomouc, Olomouc, Czech Republic.

ORCID-Profile: Martin Špaček, Peter Turcsányi, Prokop Vodička

Förderung

  • Ministerstvo Zdravotnictví Ceské Republiky
  • Univerzita Karlova v Praze

Zitieren

APA

Špaček, M., Smolej, L., Šimkovič, M., Nekvindová, L., Křístková, Z., Brychtová, Y., Panovská, A., Mašlejová, S., Bezděková, L., Écsiová, D., Vodárek, P., Zuchnická, J., Mihályová, J., Urbanová, R., Turcsányi, P., Lysák, D., Novák, J., Brejcha, M., Líkařová, T., …, & Czech CLL Study Group (2023). Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real‐world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR). British Journal of Haematology, 202(1), 40-47. https://doi.org/10.1111/bjh.18736

Vancouver

Špaček M, Smolej L, Šimkovič M, Nekvindová L, Křístková Z, Brychtová Y, et al. Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real‐world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR). British Journal of Haematology. 2023;202(1):40-47. doi:10.1111/bjh.18736

BibTeX
@article{paek2023,
  author = {Špaček, Martin and Smolej, Lukáš and Šimkovič, Martin and Nekvindová, Lucie and Křístková, Zlatuše and Brychtová, Yvona and Panovská, Anna and Mašlejová, Stanislava and Bezděková, Lucie and Écsiová, Dominika and Vodárek, Pavel and Zuchnická, Jana and Mihályová, Jana and Urbanová, Renata and Turcsányi, Peter and Lysák, Daniel and Novák, Jan and Brejcha, Martin and Líkařová, Tereza and Vodička, Prokop and Baranová, Jana and Trněný, Marek and Doubek, Michael and Czech CLL Study Group, Czech CLL Study Group},
  title = {Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real‐world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR)},
  journal = {British Journal of Haematology},
  year = {2023},
  volume = {202},
  number = {1},
  pages = {40--47},
  doi = {10.1111/bjh.18736}
}
Kostenlos starten →